DelveInsight’s “Acromegaly Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acromegaly pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Acromegaly Pipeline @ https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight

Key Takeaways from the Acromegaly Pipeline Report

• On May 28, 2026- Debiopharm International SA conducted a phase 3 study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
• On May 15, 2026- Crinetics Pharmaceuticals Inc. initiated a study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.
• DelveInsight’s Acromegaly pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Acromegaly treatment.
• The leading Acromegaly Companies such as Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, and others.
• Promising Acromegaly Therapies such as Paltusotine, CAM2029 (octreotide subcutaneous depot), GHR-LRX, Debio 4126, Octreotide capsules, Octreotide capsules, Lanreotide, Pasireotide LAR, and others.

Stay ahead with the most recent pipeline outlook for Acromegaly @ Acromegaly Treatment Drugs

The Acromegaly Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Acromegaly Pipeline Report also highlights the unmet needs with respect to the Acromegaly.

Acromegaly Overview

Acromegaly is a chronic hormonal disorder caused by excessive secretion of growth hormone (GH) in adulthood, most commonly due to a benign tumor of the pituitary gland. The excess GH leads to increased production of insulin-like growth factor-1 (IGF-1), which causes abnormal growth of body tissues. It develops slowly over many years and mainly affects adults after the closure of growth plates. Management typically involves surgery, medications, and sometimes radiation therapy to control hormone levels. This disorder occurs in approximately 50 to 70 people per million. Researchers estimate that three to eleven people out of every million develop the disorder each year.

Acromegaly Emerging Drugs Profile

• Debio 4126: Debiopharm International SA

Debio 4126 is an innovative, long-acting octreotide formulation designed for intramuscular administration every three months designed to improve the performance and convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly. The safety and efficacy of this SSA 3-month formulation is currently under investigation. The application of Debiopharm’s novel, injectable sustained release expertise would help acromegaly patients reduce injection frequency from once every 4 weeks to once every 12 weeks. Debiopharm is seeking partners with expertise in rare diseases/orphan drugs and/or in endocrinology or oncology for the further development of this compound in order to dramatically improve convenience for patients. Enabled by proprietary technology from our DEBIO SPHERE™ LAR platform – a set of flexible, rapidly customizable solutions for sustained therapeutic delivery. Currently the drug is in Phase III for acromegaly.

• GT-02037: Glytech

GT 02037 is an investigational therapeutic being developed by Glytech for the treatment of acromegaly. It is designed to modulate growth hormone signaling, aiming to reduce excessive growth hormone and IGF 1 levels associated with the disease. The drug’s mechanism focuses on improving clinical symptoms and biochemical control in patients with acromegaly. GT 02037 is currently in early clinical development, with studies evaluating its safety, tolerability, and preliminary efficacy. The drug is in Phase II stage of development for the treatment of acromegaly.

Explore groundbreaking therapies and clinical trials in the Acromegaly Pipeline. Access DelveInsight’s detailed report now! @ New Acromegaly Drugs

The Acromegaly Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acromegaly with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acromegaly Treatment.
• Acromegaly Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acromegaly Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acromegaly market

Acromegaly Companies

Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, and others.

Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acromegaly Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Acromegaly Market Drivers and Barriers

Scope of the Acromegaly Pipeline Report

• Coverage- Global
• Acromegaly Companies- Crinetics Pharmaceuticals Inc., Ipsen, Strongbridge Biopharma plc, Amryt Pharma Plc, Antisense Therapeutics Ltd, Percheron Therapeutics, Immunwork, and others.
• Acromegaly Therapies- Paltusotine, CAM2029 (octreotide subcutaneous depot), GHR-LRX, Debio 4126, Octreotide capsules, Octreotide capsules, Lanreotide, Pasireotide LAR, and others.
• Acromegaly Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acromegaly Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Acromegaly Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Acromegaly: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Paltusotine: Crinetics Pharmaceuticals Inc.
9. Product Description
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. Atesidorsen: Percheron Therapeutics
13. Early Stage Products (Phase I)
14. Comparative Analysis
15. TE 8214: Immunwork
16. Inactive Products
17. Acromegaly Key Companies
18. Acromegaly Key Products
19. Acromegaly- Unmet Needs
20. Acromegaly- Market Drivers and Barriers
21. Acromegaly- Future Perspectives and Conclusion
22. Acromegaly Analyst Views
23. Acromegaly Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/acromegaly-pipeline-insight